A great article by our CEO, Dr. Yurii Moroz, is out - 'Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors' - and it is definitely worthy of your attention! To check out the full text, follow the link.

This article addresses the challenge of developing new inhibitor chemotypes for antiviral therapeutics to treat SARS-CoV-2. The experiment yielded low micromolar inhibitors, which could aid in the optimization of MPro inhibitors. However, weaknesses in approach have also been demonstrated, particularly when dealing with challenging targets like MPro compared to other targets where the method has shown greater success. 

Many thanks to all for the excellent collaboration!   

Here you can find all of our co-authored and featured publications!